Author(s): Iguchi S, Iwamura H, Nishizaki M, Hayashi A, Senokuchi K,
Abstract Share this page
Abstract A novel, highly cardioselective ultra short-acting beta-blocker, ONO-1101, has been developed for application in the emergency treatment of tachycardia and better control of heart rate in surgery. This agent is approximately nine times more potent in beta-blocking activity in vivo and eight times more cardioselective in vitro than esmolol. This beta-blocking drug has a short duration of activity, enabling rapid recovery after cessation of administration if side effects occur. It can be used safely in patients suffering from acute heart disease and represents a major therapeutic advance in the treatment of heart disease.
This article was published in Chem Pharm Bull (Tokyo)
and referenced in Journal of Antivirals & Antiretrovirals